Feeding-jejunostomy nutrition during pre-surgery treatment for esophagus or stomach cancer
Official title: Evaluation of the Administration of Artificial Nutrition by Feeding Jejunostomy During Neoadjuvant Treatment on Postoperative Morbidity in the Context of Esophageal or Stomach Cancer
Run by University Hospital, Bordeaux · NCT07584577 · Data updated 2026-11-12
This study tests whether giving nutrition through a jejunostomy tube during pre-surgery (neoadjuvant) treatment helps reduce complications after surgery for malnourished people with esophageal or stomach cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 670 (estimated) |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Pessac) |
| Status | Recruiting |
| Started | November 1, 2026 |
| Main results expected | November 30, 2026 |
| Study ends | November 30, 2026 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT07584577 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with esophageal or stomach (esogastric) cancer who are malnourished, receiving neoadjuvant therapy, and scheduled for surgical resection are the intended participants.
✕Probably not a fit
Patients who are not malnourished or who do not receive neoadjuvant treatment are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study follows malnourished patients with esogastric cancer who receive neoadjuvant therapy and are planned for surgery to document the use of enteral (jejunostomy) or parenteral nutrition and subsequent postoperative outcomes. Investigators will record changes in nutritional status during neoadjuvant treatment, the route and duration of artificial nutrition, and rates of postoperative morbidity. Outcomes for patients who receive feeding jejunostomy support will be compared with those managed without jejunostomy to identify associations with surgical complications. Data are collected prospectively at the participating center in Bordeaux and analyzed to clarify whether preoperative refeeding influences postoperative outcomes.
Why it matters
Potential benefit: If successful, this approach could lower postoperative complication rates and improve recovery by ensuring better nutritional status before surgery.
How similar studies have gone: Existing evidence is limited and mixed, with small retrospective series and few prospective data suggesting a trend toward fewer postoperative complications for esophageal surgery but heterogeneous results overall.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient undergoing surgery for esophageal cancer * Malnourished patient at the time of management * Receiving neoadjuvant treatment Exclusion Criteria: * Patient not malnourished at the time of management * Patient who did not receive neoadjuvant treatment
Where it's running
-
Hopîtal du Haut Lévêque
Pessac, France Recruiting
Study contacts
- Principal investigator: Caroline GRONNIER, MD, PhD — University Hospital, Bordeaux
- Study coordinator: Caroline GRONNIER, PhD, MD
- Email: caroline.gronnier@chu-bordeaux.fr
- Phone: +335-57-62-24-77
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing immunochemotherapy and chemotherapy for esophageal cancer before surgery
This study is testing if a new combination of immunotherapy and chemotherapy can help people with esophageal cancer live longer and have better outcomes before surgery compared to standard chemotherapy.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.